Shell Company Reports Continued Going Concern Doubt, Zero Operations, and Related Party Dependence
GPLB filed a Legal and Risk Events on elevated volume (3.4× avg).
Summary
Green Planet Bio Engineering's Q1 2026 report reiterates its status as a non-operating shell with a going concern warning, zero cash, and complete reliance on related party funding.
Key Events · Legal and Risk Events · GPLB
-
Going Concern Warning Reiterated
The company explicitly states substantial doubt about its ability to continue as a going concern for the next twelve months, dependent on continued support from a related party.
-
Non-Operating Shell Status Confirmed
Green Planet Bio Engineering remains a public reorganized shell corporation with no active business operations and no revenue for the quarter ended March 31, 2026.
-
Zero Cash and Significant Deficit
The company reported $0 cash and a working capital deficit of $511,920 as of March 31, 2026, alongside an accumulated deficit of $1,141,540.
-
Complete Reliance on Related Party Funding
All operating expenses are financed by a related party of the majority stockholder, which advanced an additional $3,850 after the quarter end.
Analysis · GPLB · Life Sciences
This quarterly report confirms Green Planet Bio Engineering remains a non-operating shell company with no revenue and zero cash. The company explicitly states substantial doubt about its ability to continue as a going concern, relying entirely on a related party for all funding. The working capital deficit of $511,920 significantly exceeds the company's market capitalization, highlighting severe financial distress and an unsustainable operational model.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GPLB was trading at $0.02 on OTC in the Life Sciences sector, with a market capitalization of approximately $342.1K. The 52-week trading range was $0.00 to $2.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.